Relmada adds NDV-01 and sepranolone; NDV-01 Phase 2 shows 91% CR rate, Phase 3 planned 1H 2026

RELMADA THERAPEUTICS, INC.

Added two Phase 2 candidates: NDV-01 (NMIBC) and sepranolone (Prader-Willi Syndrome/compulsivity disorders).
NDV-01 six-month Phase 2 follow-up: 91% complete response rate at any time point.
Phase 3 registrational trial for NDV-01 targeted for 1H 2026; regulatory filings and manufacturing scale-up underway.
Sepranolone Phase 2 study in PWS planned for 1H 2026; proof-of-concept data in Tourette's support.
Appointed Dr. Raj S. Pruthi as CMO–Oncology and Dr. Yair Lotan as Chair of Clinical Advisory Board.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.